FMR CORP 13D and 13G filings for Celldex Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-12 09:28 am Sale |
2024-12-31 | 13G | Celldex Therapeutics, Inc. CLDX |
FMR CORP | 4,857,668 7.300% |
-1,166,748 (-19.37%) |
Filing |
| 2024-11-12 09:55 am Sale |
2024-11-08 | 13G | Celldex Therapeutics, Inc. CLDX |
FMR CORP | 6,024,416 9.088% |
-1,025,993 (-14.55%) |
Filing |
| 2024-02-09 08:50 am Sale |
2024-02-08 | 13G | Celldex Therapeutics, Inc. CLDX |
FMR CORP | 7,050,409 12.891% |
-14,565 (-0.21%) |
Filing |
| 2023-02-09 09:59 am Purchase |
2023-02-09 | 13G | Celldex Therapeutics, Inc. CLDX |
FMR CORP | 7,064,974 14.999% |
65,394 (+0.93%) |
Filing |
| 2022-02-09 09:11 am Purchase |
2022-02-08 | 13G | Celldex Therapeutics, Inc. CLDX |
FMR CORP | 6,999,580 14.999% |
1,384,247 (+24.65%) |
Filing |
| 2021-10-12 09:25 am Purchase |
2021-10-08 | 13G | Celldex Therapeutics, Inc. CLDX |
FMR CORP | 5,615,333 12.080% |
5,615,333 (New Position) |
Filing |